Here are the latest G-BA decisions from the G-BA meeting held on 16 July on the early benefit assessments of Elahere and Xerava.
A database of all previous G-BA resolutions is available in my store.
- Elahere (mirvetuximab soravtansine); ovarian, fallopian tube, or primary peritoneal carcinoma; FRα-positive; platinum-resistant; after 1 to 3 prior lines of therapy – re-assessment of an orphan drug after exceeding €30 million threshold; Indication of considerable additional benefit
- Xerava (eravacycline); new indication: complicated intra-abdominal infections (cIAI); ≥ 12 to < 18 years of age; ≥ 50 kg – Reserve antibiotic, Additional benefit deemed proven